Biological
VRC-01LS clinical trials
Also written VRC01LS and VRC-HIVMAB080-00-AB.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Institute of Allergy and Infectious Diseases (NIAID) (5)
Often tested with
Tested in the same studies.
VRC07-523LS (2) · VRC-01 (2) · Zinlirvimab (1) · VRC01 monoclonal antibody (1)
Studies
Open first, then newest update. How each study uses VRC-01LS is read from its arms, and is right about nine times in ten.
Testing it · 5
- Dual bNAb Treatment in ChildrenCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03707977Written as VRC01LS
- Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02840474Written as VRC-HIVMAB080-00-AB
- Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02797171Written as VRC01LS
- Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02256631Written as VRC01LS
- Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02599896Written as VRC-HIVMAB080-00-AB (VRC01LS)